Transfer of the human multidrug resistance 1 (MDR1) gene to hematopoietic stem cells offers an approach to overcome the myelosuppression caused by a number of antineoplastic drugs. This study was designed to determine the effect of MDRl gene transfer on overall P-glycoprotein (P-gp) expression in murine hematopoietic cells. Mice were transplanted with bone marrow cells infected with either of two different MDRl retroviral vectors. A reverse-transcriptase polymerase chain reaction-based assay was used to quantify expression levels of both endogenous and vector-derived P-gp encoding transcripts in hematopoietic cells of transplanted mice. Expression of both a truncated and full-length MDRl mRNA
K
NOWLEDGE OF THE molecular events leading to cellular drug resistance has allowed investigators to develop gene transfer strategies designed to confer drug resistance in normal host cells. Antineoplastic drugs commonly exhibit a narrow therapeutic index, reflected by frequent patient toxicity that limits the amount of drug that can be administered. This dose attenuation may lead to decreased tumor responses in some rnalignan~ies.'.~ For most anticancer drugs, the dose-limiting side effect is suppression of hematopoiesis. Transfer of drug-resistance genes to hematopoietic cells offers an attractive strategy to overcome this current limitation in cancer treatment. Drug-resistance genes may also be useful as dominant selectable markers for genetically altered hematopoietic stem cells. Patients and animals that are transplanted with hematopoietic cells exposed to retroviral vectors contain only a minority of genetically altered cells after hematopoietic reconstitution."6 Experiments using a mouse model have shown that a drug-resistance gene can be used to enrich for vector-transduced cells by administering drug to the animal after bone marrow transThis approach may offer a means to overcome the inefficiency in hematopoietic stem cell gene transfer seen with current human gene transfer protocols.
The first eukaryotic drug-resistance gene to be transferred to reconstituting bone marrow cells was a methotrexate-resistant rodent dihydrofolate reductase (mDHFR) gene. These studies showed that mice transplanted with cells transduced with a mDHFR retroviral vector were protected from methotrexate-induced myelosuppression and had increased survival after methotrexate admini~tration.~~~ Transfer of the human multidrug resistance 1 (MDR1) gene to hematopoietic cells has also been described. P-glycoprotein (P-gp), the product of the MDRl gene, functions as a drug efflux pump and confers resistance to a wide variety of naturally occurring chemotherapeutics." The feasibility of using the MDRl gene to protect hematopoietic cells has been shown by transgenic mouse
In addition, retroviral transfer of MDRl to murine clonogenic progenitors resulted in drug resistance in ~i t r 0 . I~ In murine transplant experiments, mice transplanted with MDR1-transduced cells showed attenuation of taxol-induced myelos~ppression.~.'~ In taxol-treated animals, the number of circulating leukocytes species was noted in bone marrow and spleen colony cdlr.
The truncated message resulted from cryptic mRNA splice sites within the MDRl cDNA and was detected with both vectors. Full-length message levels exceeded those from the endogenous genes in all but one case and roughly approximated that seen in the modestly drug-resistant cell line SW620. We conclude that transfer of MDRl retroviral vectors resulted in a significant increase in P-gp expression in most cases; however, aberrant splicing of MDRl transcripts can result in reduced expression of vector-derived P-gp. 0 1995 by The American Society of Hematology.
transduced with the MDRl virus increased, showing that cells expressing the transferred MDRl gene can be dominantly selected in vivo with tax01.6~' Recent work has suggested that the MDRl gene can be used to select for other therapeutic genes when the second gene is linked to the MDRl cDNA in bicistronic retroviral vector^.'^.'^ Because hematopoietic cells express endogenous P-gp," one goal of this study was to clarify if MDRl gene transfer resulted in a increase in P-gp expression above basal levels. Our prior observation that MDRl vectors allowed selection of transduced hematopoietic cells with tax01 suggested that MDRl gene transfer led to increased overall P-gp expression in transduced primary hematopoietic cells. To test this hypothesis, we compared levels of vector-derived MDRl mRNA with endogenous murine mdrl and 3 mRNA levels in hematopoietic tissues from transplanted mice and with MDRl mRNA levels seen in P-gp-expressing human tumor cell lines. Vector expression was assayed in a highly enriched stem cell population to determine if MDRl gene transfer was causing increased P-gp expression in primitive hematopoietic cells.
We report here that transfer of MDRl vectors resulted in full-length MDRl mRNA levels that exceeded that from the endogenous mdrl and 3 genes in 11 of 12 cases. Full-length MDRl transcript levels in mouse hematopoietic tissues approximated that seen in the drug-resistant human tumor cell line SW620. Expression of an MDRl vector in a primitive population of bone marrow cells highly enriched for repopulating stem cells was documented 8 months after transplant. Expression of a truncated MDRl transcript was detected and shown to be caused by cryptic splice donor and acceptor sites within the MDRl cDNA. This aberrant splicing likely reduces the overall expression of P-gp in transduced cells and may in part explain the animal to animal variability in bone marrow chemoprotection and in in vivo selection of transduced cells.
MATERIALS AND METHODS
Vector construction and retroviral producer clone isolation. Construction of the Harvey murine sarcoma-based MDRl vector and isolation of a ecotropic producer line has been previously described.'* The MDRl cDNA used in the Harvey-based vector contains a point mutation resulting in a substitution of valine for glycine at codon 185. This mutation results in decreased resistance to taxol and increased resistance to col~hicine.'~ This mutant cDNA was modified by site-directed mutagenesis to restore codon 185 to the glycine residue found in the wild-type MDRl cDNA. This wildtype MDRl cDNA was further modified by truncations of the 5' and 3' untranslated regions that preserved 12 bp upstream of the initiation codon and 8 bp downstream of the termination codon. This shortened wild-type MDRl cDNA was inserted into the Moloney murine retroviral backbone pGlZ0 (Genetic Therapy, Inc, Gaithersburg, MD) to yield to GlMD vector (see Fig 2) . This vector was introduced by calcium phosphate transfection into the amphotropic packaging line PA317'l and supernatant was collected in 48 hours. This supernatant was repetitively applied to the ecotropic packaging line GP+E8622 in the presence of 6 pdmL of polybrene (Sigma, St Louis, MO). Amphotropic supernatant was applied each time the plates were split. Greater than 90% of the GP+E86 population displayed a rhodamine dull phenotype by fluorescence-activated cell sorter (FACS) analysis after five applications of virus. Cells were then plated at limiting dilution and 30 clones were isolated for further analysis. Clones were assayed for viral titer by applying supematant from candidate producer clones to 3T3 cells and analyzing the 3T3 target population for the proportion of cells that displayed a rhodamine dull phenotype, a marker for P-gp expre~sion.'~ Forty-eight hours after infection, the 3T3 target cells were incubated with 1 pg/ mL of rhodamine 123 (Sigma) for 30 minutes. Cells were then washed with phosphate-buffered saline and allowed to efflux rhodamine in standard tissue culture media for 75 minutes. Cells were then trypsinized and the proportion of cells that were rhodamine dull was determined by FACS analysis. Titer was calculated by multiplying the proportion of dull cells by the number of cells plated and correcting for the amount of viral containing supernatant applied. Using this method, a GlMD producer clone designated "Eco 8" was isolated with a titer of 4.0 X lo5 particles per milliliter and used for subsequent transplant experiments.
Transduction of hematopoietic cells and murine transplant. DOnor C57BV6J mice were treated with 5-fluorouracil 48 hours before marrow collection, as previously de~cribed.'~ Bone marrow was harvested from the hind limbs and grown in suspension culture for 48 hours in the presence of murine interleukin-3 (XL-3) at 50 U/mL (GXBCO, Gaithersburg, MD), human XL-6 at 100 ndmL (Amgen, Thousand Oaks, CA), and rat stem cell factor (SCF) at 100 nglmL (Amgen).24.z5 Bone marrow cells were then harvested and cocultured with retroviral producer cells for another 48 hours in the presence of IL-3, IL-6, and SCF as above and with 6 pglmL of polybrene. Nonadherent cells were harvested and injected into WB/B6FI W1 W, recipient mice at 2 X lo6 cells per mouse. Eight weeks after transplant, reconstitution was verified by hemoglobin electrophoresis, as previously described.26 Transfer of the human MDRl gene sequences were verified by assaying DNA from peripheral blood leukocytes, as previously described? Animals then received 10 to 12 mgkg of taxol as an intraperitoneal injection to amplify MDR1-expressing cells and were killed at least IO days after drug administration. All mice were purchased from Jackson Laboratories (Bar Harbor, ME).
Colony-forming unit-spleen (CFU-S) assay. Recipient WBI B6F1 mice +I+ at the W locus were exposed to 9 Gy before injection of 1.0 X lo4 to 1.0 X 10' bone marrow cells. Spleens were harvested on day 14 after injection and individual colonies were isolated by microdissection.
RNA isolation. Total RNA was isolated from bone marrow or spleen colony cells using the RNazol B method according to the manufacturer's recommendations (Tel Test Inc, Friendswood, TX).
Cell sorting. Bone marrow cells were incubated with the following rat monoclonal antibodies (MoAbs) directed against murine hematopoietic cell lineage-specific surface markers: B lymphocytes (B220), CD4' T lymphocytes (L3/T4), CD8+ T lymphocytes (LY2), granulocytes (Gr-l), and myelomonocytic cells (Mac-l) (Caltag Laboratories, Inc, San Francisco, CA). Antibody-labeled cells were subtracted using magnetic immunobeads (Advanced Magnetics, Cambridge, MA). Cell populations depleted of these lineage-positive cells were then stained with a biotin-conjugated anti-c-kit MoAb, A~k -4 '~ (a gift from Dr S.I. Nishikawa, Department of Pathology, Kumamoto University Medical School, Kumamoto, Japan), as previously described." c-kit-positive cells were isolated using magnetic immunobeads.
Polymerase chain reaction (PCR) primers. PCR primers that amplify a 610-bp fragment from the murine mdrl and 3 cDNAs but do not amplify murine mdr2 or human MDRl cDNA were 5' 'ITCGGTGCCTAC'ITG 3' (MM4.5B). PCR primers that amplify a 497-bp fragment from both full-length and spliced forms of the MDRl cDNA were 5' GCCCACATCATCATGATC 3' (PS) and 5' GTCTCCTACT'ITAGTGCT 3' (P7). PCR primers specific for the full-length MDRl cDNA that amplify a 504-bp fragment were 5' GTCACAATGCAGACAGCAGG 3' (P13) and 5' CGGAAAACC-ATGTATCGGAGCC 3' (P14). PCR primers that amplify a 490-bp region specific for the aberrantly spliced MDRl cDNA were 5' CATCA'ITGGCG 3' (P16). PCR primers that amplify a 258-bp fragment from the murine p-2 microglobulin cDNA were 5' TGC-TATCCAGAAAACCCCTC 3' (5'BM) and 5' GTCATGC'ITAAC-TCTGCAGG 3' (3'BM). PCR primers that amplify a 232-bp fragment from both murine and human p-actin cDNA were 5' CATTGTGATGGACTCCGGAGACGG 3' (5'BA) and 5' CAT-CTCCTGCTCGAAGTCTAGAGC 3' (3'BA).
Quantitation of murine mdrl and 3 and vector-derived human MDRI transcripts by RT-PCR analysis. Fifteen nanograms of total cellular RNA was used for a first-strand cDNA synthesis. The reverse transcription reaction was performed in a 40 pL volume using the oligo dT primer and other reagents provided in a commercially available RT-PCR kit (Perkin Cetus Elmer, Nonvalk, CT) according to the manufacturer's protocol. Ten-microliter aliquots of the cDNA reaction mix were then used in separate PCR reactions to amplify either vector-derived MDRl cDNAs (primers P7 and P8), murine mdrl and 3 cDNAs (primers 4.3 and 4.5B), or internal control cDNAs (p-actin or p-2 microglobulin primers). All PCR reactions were performed in a 50 pL volume with 80 ng of each PCR primer for 1 minute, and extension at 72°C for 1 minute. After amplification, and P14). truncated M D R l cDNAs (primers P15 and P16). or inter-20 pL of the reaction mix was electrophoresed on a 5% nondenaturnal control cDNAs. Reaction conditions were otherwise as outlined ing polyacrylamide gel. Dried gels were analyzed using a Molecular above. MDR amplifications were performed for 25 cycles and interDynamics (Sunnyvale, CA) phosphoimager to quantify band intennal control reactions for 20 cycles using the following thermal prosity.
file: 94°C for 1.5 minutes, 55°C for 1.0 minute, and 72°C for 1.0 minute. Products were resolved by electrophoresis and band intensity was quantified as described above.
RESULTS
Expression of endogenous multidrug resistance genes in murine hematopoietic cells. Mice contain three genes that code for membrane P-gps designated mdrl, 2, and 3. Previous studies have shown that mdrl and 3, but not mdr2, can confer the multidrug resistance phen~type.".~~ To evaluate expression of the mdrl and mdr3 gene products in murine hematopoietic cells, PCR primers were designed that coamplify both transcripts in a RT-PCR assay (Fig 1A) . The relative amounts of each transcript expressed in a given sample was determined by subsequent digestion of the amplification products with the restriction enzymes Spe I and Stu I. Spe I is unique in the mdrl cDNA and Stu I is unique for the mdr3 cDNA. For example, only the mdr3 allele is expressed in intestine.3' Digestion of PCR product from intestine derived RNA shows complete digestion with Stu I and no digestion with Spe I, as expected ( Fig 1A) . Conversely, adrenal RNA shows a pattern consistent with exclusive expression of mdrl. Samples from bone marrow and thymus show that both the mdrl and 3 genes are expressed in hematopoietic tissue in roughly a 2:l ratio (Fig 1A) .
A semiquantitative RT-PCR assay was used to measure levels of mdrl and 3 transcripts in hematopoietic tissues from unmanipulated C57BV6J mice.
A standard curve showed a near linear signal response for @-actin, 0-2 microglobulin, and murine mdrl and 3 when between 3.0 and 75 ng of RNA was assayed (Fig 1D and data not shown) . This assay was used to compare endogenous mdrl and 3 expression in hematopoietic tissues with that seen in other tissues known to express relatively large amounts of these transcripts, namely adrenal, kidney, and intestine." mdrl and 3 mRNAs were expressed in bone marrow, in the spleen, at lower levels in the thymus, and at barely detectable levels in peripheral blood cells (Fig 1B) . The overall expression level of mdrl and 3 in hematopoietic tissues was much less that that seen in adrenal and kidney. To test if expression of endogenous mdr genes differed in various hematopoietic lineages, bone marrow cells expressing lineage-specific markers were isolated using MoAbs and immunobeads. The highest levels of mdrl and 3 expression were noted in CD4 and CD8 expressing T cells, intermediate amounts in B cells, and the lowest levels in macrophages (Fig IC) . Very low levels were detected in purified granulocytes (data not shown). This differential expression profile observed in divergent hematopoietic lineages is similar to what has been reported for human hematopoietic cells.'*." Differing amounts of mdrl and 3 mRNA were noted in whole bone marrow samples from different individual mice (compare BMlOX in Fig 1D with BM-whole in Fig IC) . The basis for these differences is uncertain, but could be due to variability in the proportion of cells from each hematopoietic lineage within the bone marrows of individual mice.
Expression of retroviral vectors containing the human MDRI gene in transduced mouse hematopoietic cells. To determine if retroviral-mediated transfer of the human MDRI gene resulted in significantly increased levels of Pgp encoding transcripts in murine hematopoietic tissues, mice were transplanted with bone marrow cells transduced with either a Harvey murine sarcoma-based MDRl vector (HaMDRl) or a Moloney-based MDRl vector (GlMD) (Fig  2) . The main features that distinguish GlMD from HaMDRl are (1) HaMDRl is over 3 kb larger, mostly due to rat VL30 gene sequences present in the vector and located downstream from the MDRl cDNA; (2) the MDRl cDNA in GlMD has less 5' and 3' untranslated sequences; (3) the MDRl cDNA in GlMD has been corrected to the wild-type sequence by restoring codon 185 to code for a glycine residue. This change was made in the GlMD vector based on the demonstration that the valine 185 substitution results in decreased resistance to taxol.'' Ecotropic producer clones were generated using the GP+E86 packaging line. The titers of the HaMDRl and GlMD producer clones used for subsequent transplant experiments were 2.2 X 10' and 4.0 X 10' particles/mL, respectively. For both of these producer lines, there was no evidence of either amphotropic or ecotropic replication competent retrovirus when 3T3 cells exposed to viral supernatants were analyzed for viral DNA sequences by a PCR assay."
A semiquantitative PCR assay was used to compare levels of vector-derived MDRl mRNA with endogenous murine mdrl and 3 mRNA levels and with MDRl mRNA levels in 
or p-actin transcripts (bottom row). Primers P7 and P8 were used t o amplify total vector derived transcripts. Bone marrow RNA was prepared from individual mice IM3, M8, and M71 or from marrow pooled from 3, 4, or 6 mice. RNAs from individual 14-day spleen colonies were also analyzed. Controls show RNAs from nontransplanted mice at serial fivefold dilutions and from cultured human tumor cell lines lHctl5 and SW620). Vector-transduced bone marrow was obtained from taxol-treated mice. Bone marrow from untransplanted controls was not exposed t o taxol selection. 
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two P-gp-expressing human tumor cell lines. To compare the relative amplification efficiencies for murine and human cDNA sequences, equimolar amounts of human MDR1 and murine mdrl plasmid DNA were assayed (Fig 3A) . In the range of signal intensities seen with RNA samples from transduced mice, equivalent amounts of murine mdrl plasmid yielded a signal intensity four times greater than that seen with the human MDR1 plasmid. Based on this standard curve, signal intensities for murine mdrl and 3 were divided by four when calculating the ratio of human MDR I to murine mdrl and 3 mRNA.
Fourteen-day spleen colonies were isolated from irradiated recipients and whole bone marrow was isolated from mice 14 days after taxol treatment and 4 to 8 months after transplant. MDR 1 vector expression was seen in hematopoi-
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etic tissues from transplanted mice using both vectors (Fig  3) . Endogenous mdrl and 3 levels varied between samples but were greatest in bone marrow of taxol-treated animals, less in marrow from nontransplanted control animals not receiving taxol, and least in 14 day spleen colonies. Within individual samples, the level of retroviral MDRl transcripts exceeded that from the endogenous murine mdrl and 3 genes in all but two cases (bone marrow M3 and spleen colony 3). The G 1 MD vector conferred a higher average level of MDRl mRNA expression when compared with the HaMDR1 vector. No differences in vector expression were detected in bone marrow versus spleen colony cells.
MDRl mRNA levels in transduced mouse tissues were compared with that from the human tumor cell lines HctlS and SW620. HctlS cells express a high level of MDRl c +ND+
7"
mRNA and stain brightly with MoAbs against P-gp." SW620 cells express IS-fold less MDRl mRNA and P-gp is at the lower limit of detection using MoAbs. Despite this, SW620 cells exhibit significant P-gp-mediated drug resistance as shown by a 2-to 1 l-fold increase in drug sensitivity seen with P-gp reversing agent verapamil." Our semiquantitive RT-PCR assay indicated that SW620 cells express 20-fold less MDRl mRNA than HctlS (Fig 3B) , closely approximating the value reported using a RNA slot blot assay." Expression levels of the MDRl vectors in tissues from transplanted mice were intermediate between that observed in SW620 and Hct 15 cells (Fig 3B) .
Expression of the HaMDRI vector in hematopoietic stem cells. To determine the level of expression of the HaMDRl vector in hematopoietic stem cells, RNA was analyzed from a sorted population of bone marrow cells known to be highly enriched for repopulating hematopoietic stem cells. Four mice known to be positive for DNA proviral sequences in circulating leukocytes 8 months after transplant were killed I O days after taxol administration and bone marrow cells were pooled. Mature lineage-specific cells were subtracted using an MoAb cocktail as previously described.'" Cells expressing c-kit on the cell surface were then isolated from the lineage-negative population. has been described in human hematopoietic cells" (Fig 4) . Vector-derived human MDRl transcripts were detected in all populations. The MDRI mRNA level in the c-kit', linpopulation was calculated to be four times greater the level of the endogenous mdrl and 3 transcripts, after correcting the signal intensity using the standard curve shown in Fig  3A. These data show significant expression of the MDRl vector in an enriched stem cell population at an extended period after gene transfer.
Aberrant mRNA splicing in MDRl vectors. Southern blot analysis of genomic DNA from cultured fibroblasts transduced with the MDRl vectors showed the expected fulllength provirus as well as a shortened proviral form (data not shown). Mapping of the short form showed a junction region arising from the joining of a cryptic splice donor site ( C M T A T G C , codon 1 13 underlined) and a cryptic splice acceptor site (ACATITTTCCTTWG, codon 773 underlined) within the MDRl cDNA (K. McDonagh, manuscript in preparation). Aberrant splicing of vector-derived genomic RNA within the producer cells results in passage of this truncated proviral form to target cells. Sequence analysis of the truncated mRNA predicts a nonfunctional protein based on the large deletion of coding sequence and a downstream frameshift mutation resulting in a premature termination codon.
The PCR primers used to measure transcript levels in the previously described experiments (P7 and P8 in Fig 5 ) amplify both full-length and spliced MDRI transcripts. To determine the prevalence of spliced MDRl mRNA in trans- Acceptor duced hematopoietic tissues, primer sets were designed to discriminate between full-length and aberrantly spliced MDRl transcripts. P13 and P14 are specific for full-length MDRl message given that sequences complementary to P13 are deleted in the spliced form (Fig 5) . Primers P15 and P16 span the splice junction and produce a 490-bp amplification product specific to the spliced form. Figure 6 shows the results of a RT-PCR assay for spliced and full-length MDRl transcripts. Plasmid DNA containing the MDRl cDNA shows amplification product only with the full-length primers as expected. RNA from the Hctl5 cell line shows that less than I % of the total MDRI transcripts 
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Junction are truncated spliced forms. In contrast, cytoplasmic RNA from the HaMDRl producer clone shows equivalent amounts of both full-length and spliced message. cDNA prepared from hematopoietic tissues of transplanted mice showed variable proportions of spliced transcripts. Some samples expressed predominantly truncated nonfunctional message (Spleen Colony 5 and Bone Marrow MI6 in Fig  6) . This variability in the degree of truncated transcript is explained in part by variable degrees of passage of truncated provirus. The ratio of truncated to full-length provirus correlated with the ratio of truncated to full-length MDRl transcripts (data not shown). In the primary mouse hematopoietic "
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Harvey Vector cell populations analyzed, the spliced transcript averaged about 60% of total vector-derived message. No significant difference in the degree of aberrant mRNA splicing was noted between the two vectors, showing that aberrant splicing is independent of the vector backbone.
To quantify the level of expression of endogenous and vector-derived P-gp-encoding transcripts, intensities of appropriate bands on gels were measured using a Molecular Dynamics phosphoimager. For a given sample, the level of vector-derived transcripts was calculated as the ratio of MDRl product to &actin product. The proportion of vectorderived transcripts that were full-length or spliced was calculated as the ratio of full length or spliced product to the sum of full length plus spliced product. The signal intensity ratio of murine mdrl and 3 to p-actin was divided by four to allow comparison with the MDRl to p-actin ratio. Figure 7 shows the relative levels of expression of endogenous mdrl and 3 transcripts, full-length MDRI, and spliced MDRl transcripts in various samples. The level of full-length MDRl transcripts exceeded that from the endogenous genes in 11 of 12 cases. In most cases, the level of full-length MDRl mRNA expression approximated that seen in the modestly drug-resistant cell line SW620. The GlMD vector resulted in somewhat higher levels of full-length MDRl expression due to increased expression of both full-length and spliced forms. Taken together, these results indicate that MDRl gene transfer resulted in significant augmentation of P-gp-encoding mRNA levels in transplanted murine hematopoietic cells.
These experiments measured MDR 1 mRNA levels in populations of cells. Because not all cells in bone marrow-derived populations necessarily contain the transferred gene, it is possible that the overall MDRl mRNA levels in the subset of cells that were actually transduced were higher than the calculated values. For example, the average proviral DNA copy number in the whole bone marrow cells used for stem cell purification was 1.2 copies per cell (data not shown). If 100% of the bone marrow cells contained one copy of the vector, then the mRNA levels measured for the population would represent the average expression seen in each transduced cell. An average copy number of 1.2 is also consistent with 50% of the cells containing two copies of the vector. In this case, the average MDRl mRNA levels in transduced cells would be twice that of the population average. In contrast to bone marrow samples, mRNA ratios calculated for CFU-S-derived colonies can be extrapolated to each cell in the population because these colonies are derived from a single transduced cell; therefore, all cells contain the transferred provirus.
Protein expression. Attempts to show P-gp expression in mouse bone marrow and peripheral blood cells using the 
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MoAb MRK-16 showed little to no detectable surface staining (data not shown). This finding is consistent with the observation that overall full-length MDRl transcript levels in transduced cells approximated that seen in the SW620 cell line, which expresses P-gp at the threshold of detection using available MoAbs. '5 Aberrant splicing in producer clones. The demonstration of truncated provirus in target cells transduced with MDRl vectors suggested that aberrantly spliced genomic transcripts were packaged and transferred by producer cell clones. To confirm this finding and to determine if the degree of aberrant splicing varied among individual producer clones, a number of isolated producer clones were analyzed for the prevalence of spliced transcripts in the cell cytoplasm. Ecotropic producer clones were isolated after screening supernatants for the ability to confer rhodamine dull phenotype on 3T3 cell populations. RNAs prepared from six individual GlMD producer clones and the one HaMDR1 producer clone were analyzed. These results showed similar levels of spliced and full-length transcripts in all clones analyzed (Fig  8) . This experiment established that aberrant splicing of the MDRl cDNA is not specific to individual producer clones.
DISCUSSION
Several groups have shown that retroviral-mediated MDRl gene transfer to murine hematopoietic cells results in drug-resistant hematopoietic cells in transplanted animal~.'.'.'~ This work provides the preclinical rationale for testing this strategy as a therapeutic modality in cancer patients. This approach may allow reduction of chemotherapy related toxicity and enable drug dose intensification. Another potential application is the use of MDRl as a dominant selectable marker in vivo. Chimeric vectors containing both the MDRl cDNA and other nonselectable therapeutic genes may allow selection of transduced cells after transplantation as a means to overcome current limitations in hematopoietic stem cell transduction efficiencies.
Our prior observation that taxol treatment can lead to stable increases in provirally marked murine hematopoietic cells suggested that selection may occur at the stem cell level in some instances. This interpretation implies that MDRl gene transfer should increase P-gp expression in primitive murine hematopoietic cells. It has been shown that primitive human hematopoietic cells express relatively high levels of endogenous P-glycoprotein compared with more differentiated hematopoietic cells." Given these considerations, we directly tested if MDRl gene transfer was resulting in a increase in P-gp expression in several populations of hematopoietic cells. The experiments reported here show that MDRl gene transfer resulted in a several fold increase in the overall level of P-gp encoding transcripts in whole bone marrow, differentiated spleen colonies, and a population of primitive bone marrow cells. Full-length MDRl mRNA levels were equivalent to that seen in the modestly drug-resistant cell line SW620. These data provide support for the interpretation that the transferred MDRl gene is expressed at physiologically significant levels in proliferative murine hematopoietic cells. In agreement with these conclu-
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Spliced MDRl sions, human CD34+ cells have recently been shown to display increased drug resistance in vitro after transfer of the Harvey MDRl vector. 37 We have also shown that murine hematopoietic cells endogenously express both mdrl and mdr3 transcripts. The overall levels of mdrl and 3 expression in hematopoietic tissues was much lower than that seen in adrenal and kidney, tissues known to endogenously express high levels of P-gp. This modest endogenous P-gp expression in hematopoietic cells is consistent with the known sensitivity of hematopoietic cells to P-gp-influenced antineoplastic drugs. Analogous to what has been reported for human hematopoietic cells, the endogenous murine mdrl and 3 genes were differentially expressed in divergent hematopoietic lineages and were expressed at relatively high levels in primitive undifferentiated cells. The physiologic significance of these differences are not understood. Our data show relatively high levels of mdrl and 3 expression in bone marrow derived T cells, intermediate levels in thymic cells, and very low levels in peripheral blood leukocytes (which contain 50% to 70% lymphocytes). Similar variability in P-gp expression in specific human lymphocyte subsets has been reported? It may be that P-gp expression in T lymphocytes is a function of T-lymphocyte activation and maturation.
Unexpectedly, we found that all cells transduced with MDRl vectors contained a shortened provirus and expressed a truncated MDRl mRNA. Aberrant splicing of vector derived transcripts was shown to be mediated by cryptic splice donor and acceptor sites within the wild-type MDRl cDNA. It is likely that aberrant MDRl mRNA processing results in attenuation of P-gp expression. Both the transfer of truncated provirus and aberrant splicing of transcripts derived from full-length provirus could result in expression of truncated transcripts. It is uncertain to what degree each mechanism contributes to expression of truncated MDRl in transduced hematopoietic cells. The variable degree to which full-length MDRl transcripts are expressed in different samples likely contributes to variability in the degree of in vivo selection observed among individual mice and in the difficulty we have had in showing consistent protection from myelosuppression after MDRl gene transfer. Animals repopulated with a stem cell clone expressing predominantly truncated MDRl mRNA would not expected to be protected from drug-induced myelosuppression.
Several forms of spliced P-gp transcripts have been detected in drug-resistant hamster cells.38 Unlike the truncated transcript arising from MDRl retroviral vectors, these endogenously occurring spliced mRNAs maintain the open reading frame and naturally occumng stop codon present in the full-length mRNA. It is not known if the spliced rodent transcripts encode proteins capable of conferring functional drug resistance. It is interesting that the sequence and location of the splice acceptor site noted in one of these transcripts is very similar to that seen in the human MDRl cDNA. Our observation that very small amounts of truncated MDRl transcripts are present in the P-gp-expressing human tumor cell line Hct 15 suggests that the cryptic splice sites can be activated at a very low frequency with transcription of genomic MDRl sequences. Increased usage of these cryptic splice sites within the context of retroviral vectors may be due to the lack of intron removal by splicing machinery, as has been seen in P-thalassemia mutations that abolish normal RNA spli~ing.~'.~' It is also possible that secondary structure of the genomic viral RNA may result in increased aberrant mRNA processing.
We are in the process of engineering MDRl vectors that do not splice at these cryptic sites to test if expression can be augmented and if the level of drug resistance in bone marrow can be increased. Testing of these second-generation MDRl vectors in mice may allow identification of an improved MDRl vector for clinical use.
